A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.

Publikation

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.

Wissenschaftlicher Artikel/Review - 14.09.2023

Hanna Glenn J, Stathis Anastasios, Lopez-Miranda Elena, Racca Fabricio, Quon Doris, Leyvraz Serge, Hess Dagmar, Keam Bhumsuk, Rodón Jordi, Ahn Myung-Ju, Kim Hye Ryun, Schneeweiss Andreas, Ribera Josep-Maria, DeAngelo Daniel, Perez Garcia Jose Manuel, Cortes Javier, Schönborn-Kellenberger Oliver, Weber Dirk, Pisa Pavel, Bauer Michael, Beni Laura, Bobadilla Maria, Lehal Raj, Vigolo Michele, Vogl Florian D, Garralda Elena

Zitation

Hanna G, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodón J, Ahn M, Kim H, Schneeweiss A, Ribera J, DeAngelo D, Perez Garcia J, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl F, Garralda E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer Res Commun 2023; 3:1853-1861.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Cancer Res Commun 2023; 3

Veröffentlichungsdatum

14.09.2023

eISSN (Online)

2767-9764

Seiten

1853-1861

Kurzbeschreibung/Zielsetzung

CB-103 selectively inhibits the CSL-NICD (Notch intracellular domain) interaction leading to transcriptional downregulation of oncogenic Notch pathway activation. This dose-escalation/expansion study aimed to determine safety, pharmacokinetics, and preliminary antitumor activity.